TriSalus Life Sciences Inc. (TLSI)
NASDAQ (NMS) NASDAQ (NMS) Primary 
TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?
TriSalus Life Sciences, Inc. (TLSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks
TriSalus Life Sciences aims to achieve positive cash flow by 2025, driven by expanding sales of their TriNav system and reducing operating expenses. The PERIO-03 trial for nelitolimod, a potential treatment for liver-involved cancers, is a key catalyst, with top-line data expected later this year. Financially, TLSI reported a net loss of $30 million for FY 2024, but expects to be EBITDA positive with 50% sales growth in 2025.
TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Mary Szela - President & Chief Executive Officer James Young - Chief Financial Officer Richard Marshall - Medical Director Conference Call Participants Carl Burns - Northland Capital Markets Justin Walsh - JonesTrading Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company William Plovanic - Canaccord Genuity Operator Good morning, and welcome to TriSalus Life Sciences Fourth Quarter and Full Year 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode.
TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.56 per share a year ago.
TriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are Cut
TriSalus Life Sciences continues to develop its TriNav infusion system, expanding its reach in liver and pancreatic cancer treatment, despite shifting focus from drug development. TLSI's financials show a $2.4 million net loss for the quarter, but management is optimistic about turning cash flow positive by 2025. The company faces risks with low cash reserves and potential need for dilutive fundraising, despite cost reduction efforts and growing product sales.
TriSalus Life Sciences, Inc. (TLSI) Q3 2024 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Jim Young - Senior Vice President, Investor Relations & Treasurer Mary Szela - President & Chief Executive Officer Sean Murphy - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Suraj Kalia - Oppenheimer & Company William Plovanic - Canaccord Genuity Justin Walsh - JonesTrading Operator Good morning, and welcome to TriSalus Science's Third Quarter 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode.
TriSalus Life Sciences initiated with a Buy at Roth MKM
Roth MKM analyst Jason Wittes initiated coverage of TriSalus Life Sciences with a Buy rating and $11 price target. The company's TriNav catheter significantly improves drug delivery with pressure enabled drug delivery, which is on its way to becoming the standard of care for delivering therapeutics to tumors in the liver, the analyst tells investors in a research note. The firm says this alone supports 50% growth through 2027, with upside from clinical expansion beyond the liver.
TriSalus Life Sciences, Inc. (TLSI) Q2 2024 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q2 2024 Earnings Call Transcript August 15, 2024 9:00 AM ET Company Participants Jim Young - SVP, IR and Treasurer Mary Szela - President and CEO Alex Kim - SVP, Interventional Radiology Steven Katz - CMO Sean Murphy - CFO Conference Call Participants Justin Walsh - JonesTrading Operator Good morning, and welcome to TriSalus Science Second Quarter 2024 Earnings Conference Call. Currently, all participants are on listen-only mode.
TriSalus Life Sciences: Falling Despite Moving Forward Into The Market
TriSalus Life Sciences, Inc. is focusing on developing organ-targeted therapy delivery mechanisms and pairing them with their own drugs. Nelitolimod, a TLR9 activator, is showing promising results in various solid tumor contexts, including liver and pancreatic cancers. Despite financial concerns, TriSalus Life Sciences' growing sales and promising clinical data make them a potential bargain investment when considered for the longer term.
